Fosinopril sodium

Names

[ Name ]:
Fosinopril sodium

[Synonym ]:
Tensozide
Dynacil
Fosinopril sodium
(4S)-4-Cyclohexyl-1-{[(R)-[(1R)-2-methyl-1-(propionyloxy)propoxy](4-phenylbutyl)phosphoryl]acetyl}-L-proline
Fosinorm
Staril
sodium,(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate
(4S)-4-cyclohexyl-1-{[(R)-{[(1R)-2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline
MFCD00897699
L-Proline, 4-cyclohexyl-1-[2-[(R)-[(1R)-2-methyl-1-(1-oxopropoxy)propoxy][(1R)-4-phenylbutyl]phosphinyl]acetyl]-, (4S)-
Fositen
L-proline, 4-cyclohexyl-1-[2-[(R)-[[(1R)-2-methyl-1-(1-oxopropoxy)propyl]oxy][(1R)-4-phenylbutyl]phosphinyl]acetyl]-, (4S)-
Fozitec
Elidur

Biological Activity

[Description]:

Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.Target: ACEFosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy [1-3].

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE)

Natural Products >> Alkaloid

Research Areas >> Cardiovascular Disease

[References]

[1]. Ondetti, M.A., Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation, 1988. 77(6 Pt 2): p. I74-8.

[2]. Piepho, R.W., Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000. 57 Suppl 1: p. S3-7.

[3]. Sharma, S., et al., The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther, 1999. 6(4): p. 181-9.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
705.7±70.0 °C at 760 mmHg

[ Melting Point ]:
196-198ºC

[ Molecular Formula ]:
C₃₀H₄₅NNaO₇P

[ Molecular Weight ]:
563.662

[ Flash Point ]:
380.6±35.7 °C

[ Exact Mass ]:
563.301208

[ PSA ]:
122.85000

[ LogP ]:
6.09

[ Vapour Pressure ]:
0.0±2.4 mmHg at 25°C

[ Index of Refraction ]:
1.532

[ Storage condition ]:
-20°C Freezer

MSDS

Click to get detail MSDS

Safety Information

[ RIDADR ]:
NONH for all modes of transport

[ HS Code ]:
2933990090

Customs

[ HS Code ]: 2933990090

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.

Clin. Pharmacol. Ther. 96(6) , 713-22, (2014)

Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by hepatic carboxylesterase 1 (CES1). Most angiotensin-converting enzyme inhibitors (ACEIs) a...

Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice.

Pharmacol. Res. 65(3) , 285-96, (2012)

The renin-angiotensin system (RAS) exists in the brain and it may be involved in pathogenesis of neurological and psychiatric disorders including seizures. The aim of the present research was to evalu...

Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk.

Am. J. Cardiol. 108(2) , 294-301, (2011)

The renin-angiotensin system is an important mediator of tumor progression and metastasis. A recent meta-analysis of randomized controlled trials reported an increased risk of cancer with angiotensin ...